Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Post by MrMugsyon May 13, 2021 12:04am
234 Views
Post# 33189453

Q1 Conference Call ...

Q1 Conference Call ...Q1 sales were off but they think they can make up for the shortfall during the rest of the year.
COVID effect in Jan/Feb ... but ... sales in March were improved and sales in April are better than March.

Cautious but optimistic w.r.t. COVID

10 locations now ... but ... Q1 signings were best quarter ever.
Have more signed contracts in hand than we have established locations now
Therefore, we expect to be able to hit our 25 site goal (if not better) by yearend.

Mentioned some new upcoming sites for 2021 ... Mayo Jacksonville, Mayo Rochester, Memorial Hartman and Methodist San Antonio.

Akumin's first 10 centers ... about 5 will be in Florida and the other 5 will be in Texas and Pennsylvania (first one in Florida in Q4)

Reimbursement - hospitals are getting paid
Arun discussed plans to start application for CPT-1 by end of the year and file in 2022
TACT 2.0 recruitment complete by yearend

Growth Strategy is focused on California - Florida - Texas and North-East (Arizona as well) at this time


<< Previous
Bullboard Posts
Next >>